Influence of Platelet-Activating Factor on Cardiovascular System

Leyi Gu

2009-01-01

Abstract:Platelet-activating factor(PAF) has various effects on cardiovascular system. PAF is related with atherosclerosis,ischemia-reperfusion injury,heart failure,and other cardiovascular pathological process.It also plays an important role in thrombosis.The effects of PAF on cardiovascular diseases are reviewed.

What problem does this paper attempt to address?

The Role of Plateletactivating Factor in Hepatic Ischemiareperfusion Injury and the Protective Effect of Anisodamine

史留斌,彭淑牖,孟兴凯,刘颖斌,彭承宏

DOI: https://doi.org/10.3760/j.issn:1003-0603.2001.04.008

2001-01-01

Abstract:Objective:To study the role of plateletactivating factor (PAF) inhepatic ischemiareperfusion injury and the protective effects of anisodamine.Methods:Tissue PAF and malondialdehyde (MDA) contents were measured in rats with or without anisodamine treatment during hepatic ischemiareperfusion injury.The pathological change in hepatic tissue was also observed.Results:As the liver reperfusion prolonged,tissue PAF levels elevated from (227.72±31.13)pg/g to (467.16±53.48)pg/g. After intravenous administration of anisodamine,the release of PAF was remarkably decreased.Serum enzymes,MDA content and the degree of liver injury were significantly lower than those of untreated groups (P<0.01).Conclusions:PAF may play an important role in liver ischemiareperfusion injury,and its deleterious effects can be blocked by treatment with anisodamine.
Role of platelet-activating factor receptor in adhesion and invasion of Aggregatibacter actinomycetemcomitans in human umbilical vein endothelial cells

Qin WANG,Dongying XUAN,Deyu ZHONG,Yarong QU,Jingyi YU,Hong CAO,Jincai ZHANAG

DOI: https://doi.org/10.3969/j.issn.1673-4254.2016.01.13

2016-01-01

Abstract:To explore the role of platelet-activating factor receptor (PAFR) in adhesion and invasion of phospho- rylcholine (PC)-positive Aggregatibacter actinomycetemcomitans in cultured human umbilical vein endothelial cells (HUVEC).Cultured HUVECs were pretreated with the PAFR antagonist CV3988 or anti-human PAFR monoclonal antibody for 30 min before infection with PC-positive or -negative A. actinomycetemcomitans strains. The bacterial adhesion and invasion and cytotoxicity in the cells were examined using MTT assay.Pretreatment with PAFR antagonists at 100, 200 and 500 nmol/L significantly reduced the adhesion rate (36.29∓3.52)%, (19.04∓3.35)% and (7.69∓3.19%), respectively] and invasion rate [(12.12∓1.58)%, (7.08∓0.29)% and (2.60∓2.26)%, respectively] of PC-positive A.actinomycetemcomitans in HUVECs. Similarly, pretreatment with anti-PAFR antibody also significantly reduced A.actinomycetemcomitans adhesion and invasion in HUVECs [(50.05∓5.28)% and (39.09∓6.50)%, respectively]. Pretreatment with PAFR antagonist (200 and 500 nmol/L) and anti-PAFR antibody (25 µg/mL) significantly increased the viability of HUVECs incubated with PC-positive A.actinomycetemcomitans from (25.39∓9.33)% to (91.12∓3.14)%, (94.12∓2.15)% and (65.5∓1.87)%, respectively, but such pretreatments did not increase the viability of cells incubated with PC-negative A.actinomycetemcomitans.PAFR plays an important role in the adhesion, invasion, and cytotoxicity of PC-positive A.actinomycetemcomitans in cultured HUVECs.
Effects of platelet activating factor on action potentials and potassium channels in guinea-pig ventricular myocytes

杜以梅,唐明,刘长金,柯琴梅,骆红艳,胡新武

DOI: https://doi.org/10.3321/j.issn:0371-0874.2004.03.002

2004-01-01

Abstract:This study was designed to investigate the effects of platelet activating factor (PAF) on the action potential and potassium currents in guinea-pig ventricular myocytes. Whole cell patch clamp techniques were used. With 5 mmol/L ATP in the pipette electrode (mimic normal condition), 1 μmol/L PAF increased APD90 from 225.8±23.3 to 352.8±29.8 ms (n=5, P＜0.05), decreased IK1 and IK tail currents from -6.1±1.3 to -5.6±1.1 nA (n=5, P＜0.05) at -120 mV and from 173.5±16.7 to 152.1±11.5 pA (P＜0.05, n=4) at +30 mV,respectively. But PAF had no effect on IK1 at potentials within the normal range of membrane potentials (between -90 mV and +20 mV).restore prolongation of APD induced by PAF. In conclusion, in guinea-pig ventricular myocytes, with 5 mmol/L ATP in the pipette PAF hence a decrease in APD. It is suggested that PAF may amplify the heterogeneity between ischemic and normal cardiac myocytes during ischemia/reperfusion, which may play a vital role in the pathogenesis of the arrhythmias induced by ischemia/reperfusion.
Effects of Carvedilol on Homocysteine,endothelin and Von Willebrand Factor in Patients with Unstable Angina Pectoris

SUN Jian,HU Shenjiang,WANG Guobin,ZHU Chaohui

DOI: https://doi.org/10.3760/j.issn:1671-0282.2005.03.017

2004-01-01

Journal of Clinical Cardiology

Abstract:Objective:To investigate the levels of homocysteine(Hcy) endothelin(ET) and fibrinopeptide A(FPA) in patients with unstable againa pectoris (UAP) . Methods:The serum levels of Hcy, ET and FPA in 37 cases with UAP and 31 healthy individuals were detected respectively. Result:The levels of Hcy, ET and FPA in patient with UAP were higher than that in healthy individuals [( 12.49± 5.47) vs ( 4.38± 1.14)μmol/L,( 129.37± 26.62) vs ( 65.06± 13.76) ng/L and ( 8.87± 2.11) vs ( 3.45± 0.60)μg/L, all P 0.05]. Hcy level had positively related to ET(r= 0.45,P 0.05). Conclusion:The changes of Hcy, ET and FAP may be related to pathophysiology of UAP.
Role of platelet activating factor in diagnosis and treatment of acute cerebral infarction

YIN Liying,LI Huiyuan,ZHANG Jiping,WANG Xuan,LIU Yuan,LI Jianhua

DOI: https://doi.org/10.14010/j.cnki.wjyx.2011.02.021

2011-01-01

Abstract:Objective To study the relationship between platelet activating factor(PAF) and acute cerebral infarction (ACI),and the PAF as a target for ACI therapy.Methods PAF levels in plasma were quantified using enzyme - linked immunosorbent assay.Effects of safflower yellow(SY) on nervous function,PAF and hemorheology were tested to further prove the role of PAF in the treatment of ACI.Results The PAF levels in ACI group were significantly higher than those in healthy control group,and proportional to infarction volume.Improved nervous function and hemorheology,decreased PAF levels were observed after SY treatment.Conclusions PAF levels and activity are elevated in ACI patients,and the drug aimed at PAF plays a key role in the treatment of ACI.
Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients

Harishkumar,Hans,Stanton,Grabrucker,Lordan,Zabetakis

DOI: https://doi.org/10.3390/nu14204414

IF: 5.9

2022-10-21

Nutrients

Abstract:Platelet-activating factor (PAF) is a lipid mediator that interacts with its receptor (PAF-R) to carry out cell signalling. However, under certain conditions the binding of PAF to PAF-R leads to the activation of pro-inflammatory and prothrombotic pathways that have been implicated in the onset and development of atherosclerotic cardiovascular diseases (CVD) and inflammatory diseases. Over the past four decades, research has focused on the identification and development of PAF-R antagonists that target these inflammatory diseases. Research has also shown that dietary factors such as polar lipids, polyphenols, and other nutrient constituents may affect PAF metabolism and PAF-R function through various mechanisms. In this review we focus on the inhibition of PAF-R and how this may contribute to reducing cardiovascular disease risk. We conclude that further development of PAF-R inhibitors and human studies are required to investigate how modulation of the PAF-R may prevent the development of atherosclerotic cardiovascular disease and may lead to the development of novel therapeutics.

nutrition & dietetics
Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases

Yulong Liu,Lisa B.E. Shields,Zhongwen Gao,Yuanyi Wang,Yi Ping Zhang,Tianci Chu,Qingsan Zhu,Christopher B. Shields,Jun Cai

DOI: https://doi.org/10.1007/s12035-016-0062-5

IF: 5.682

2016-09-09

Molecular Neurobiology

Abstract:Platelet-activating factor (PAF) is a bioactive lipid mediator which serves as a reciprocal messenger between the immune and nervous systems. PAF, a pluripotent inflammatory mediator, is extensively expressed in many cells and tissues and has either beneficial or detrimental effects on the progress of inflammation-related neuropathology. Its wide distribution and various biological functions initiate a cascade of physiological or pathophysiological responses during development or diseases. Current evidence indicates that excess PAF accumulation in CNS diseases exacerbates the inflammatory response and pathological consequences, while application of PAF inhibitors or PAFR antagonists by blocking this signaling pathway significantly reduces inflammation, protects cells, and improves the recovery of neural functions. In this review, we integrate the current findings of PAF signaling in CNS diseases and elucidate topics less appreciated but important on the role of PAF signaling in neurological diseases. We propose that the precise use of PAF inhibitors or PAFR antagonists that target the specific neural cells during the appropriate temporal window may constitute a potential therapy for CNS diseases.

neurosciences
[Renal diseases and platelet activating factor]

E Pirotzky,P Colliez,C Guilmard,P Braquet

Abstract:The platelet-activating factor (PAF) is a molecule produced by several types of cells (monocytes, platelets, polynuclears, eosinophils and endothelial cells) and by different organs (lungs, heart, kidney). Its action concerns many inflammatory phenomena such as allergy, cerebral, cardiac or renal ischemia. The discovery of specific antagonists helped us to understand the pathophysiological effects of PAF in man. As PAF is involved in the mechanism of proteinuria and many other nephropathies, the use of antagonists for the treatment of such disorders seems valuable.
Therapy for Acute Pancreatitis with Platelet-Activating Factor Receptor Antagonists

Chong Chen,Shi-Hai Xia,Hong Chen,Xiao-Hong Li

DOI: https://doi.org/10.3748/wjg.14.4735

IF: 5.374

2008-01-01

World Journal of Gastroenterology

Abstract:Acute pancreatitis (AP) causes release of platelet-activating factor (PAF), which induces systemic effects that contribute to circulatory disturbances and multiple organ failure. PAF is a cell surface secretion of bioactive lipid, which could produce physiological and pathological effects by binding to its cell surface receptor called platelet-activating factor receptor (PAF-R). Studies showed that PAF participate in the occurrence and development of AP and administration of platelet-activating factor receptor antagonists (PAF-RAs) could significantly reduce local and systemic events after AP. PAF has also been implicated as a key mediator in the progression of severe AP, which can lead to complications and unacceptably high mortality rates. Several classes of compounds show significant PAF-RAs, and significant local and systemic effects on reducing inflammatory changes. As a preventive treatment, PAF-RA could block a series of PAF-mediated inflammatory injury and thus improve the prognosis of AP. This review introduces the important role of PAF-RA in the treatment of AP.
Effects of Anisodamine on the Injury of Rat Pulmonary Microvascular Endothelial Cells Induced by Platelet-Activating Factor

王应灯,孙耕耘

DOI: https://doi.org/10.3969/j.issn.1000-1492.2004.01.009

2004-01-01

Abstract:Aim To investigate the mechanism of platelet-activating factor(PAF) induced injury on the cultured rat pulmonary microvascular endothelial cells(RPMVEC),and the interfering action of breviscapine. Methods RPMVEC were isolated from Wistar rat and cultured in vitro, the effects of PAF on morphology,monolayer permeability and F-actin of RPMVEC were observed, F-actin expression was evaluated by flow cytometry. Results PAF in the concentration over 0.1 mg·L -1 induced detachment and rupture of RPMVEC within 48 h. 10 mg·L -1 of PAF increased permeability of RPMVEC monolayer and induced depolymerization of F-actin within 120 min.Breviscapine inhibited these effects of PAF. Conclusion ①The detachment and rupture of RPMVEC induced by PAF depends on the exposed concentration and time.②The increased permeability of RPMVEC monolayer induced by PAF is significantly correlated with the depolymerization of F-actin. ③The increased permeability of RPMVEC monolayer and depolymerization of F-actin induced by PAF can be markedly inhibited by breviscapine, which exerts protective action on RPMVEC injury induced by PAF.
Roles of platelet-derived growth factor and platelet-derived growth factor receptors in cardiovascular diseases

FAN Bin,MA Li-kun

DOI: https://doi.org/10.13191/j.chj.2013.04.023

2013-01-01

Abstract:Platelet-derived growth factors( PDGFs) and platelet-derived growth factor receptors( PDGFRs) both play important roles in cardiovascular diseases including atherosclerosis( AS),angiogenesis and myocardial fibrosis. PDGFRs that are activated by their ligand PDGFs upregulate in cells such as vascular smooth muscle cells,fibroblasts and endothelial cells,thus resulting in the proliferation and differentiation of target cells. PDGFs/PDGFRs participate in AS angiogenesis and myocardial fibrosis.This review will discuss the research progress of PDGFs/PDGFRs in cardiovascular diseases.
Determination of the Platelet Activating Factor in Silicotic Patients and Its Effect on Fibroblasts

Qunwei Zhang,Yiqun Mo,Jinpin Lou,Xinqiang Zhu,Zhimin Chen,Linyun He,Huixian Zhong

DOI: https://doi.org/10.1007/bf02918288

2001-01-01

Environmental Health and Preventive Medicine

Abstract:Platelet-activation factor (PAF), one of the potent proinflammatory mediators, is produced from a large range of cells, including polymorphonuclear neutrophils, monocytes, and natural killer cells. To study the role of PAF in the pathogenesis of silicosis, we determined the PAF in silicotic patients and in healthy persons. The results showed that the concentration of PAF in the plasma of silicotic patients was significantly higher than that of healthy persons. Ourin vitro experimental results showed that the total numbers of fibroblasts were markedly raised with added PAF from 0 to 1 μ g/ml. Adding 1 μ g/ml PAF significantly increased the total numbers of fibroblasts after culture for 48, 72, 96 hrs. Therefore, we suggest that PAF be possibly involved in the pathogenesis of silicosis. However, the mechanism remains to be further elucidated.
Dual Activities of PAF in Central Nervous System and Its Values in Development of New Drugs

LI Juan,CHEN Hong-zhuan

DOI: https://doi.org/10.3969/j.issn.1009-2501.2007.03.006

2007-01-01

Abstract:Platelet-activating factor (PAF), an endogenous bioactive lipid generated by phospholipase A2 and other pathways, displays a variety of biological activities in the nervous system. It has been suggested that PAF plays important roles in neuronal physiological functions including acting as a retrograde messenger to enhance synapse plasticity and memory formation, via activation of its specific membrane receptors.Therefore,the drugs that mimic the action of PAF or modulate the production and inactivation of PAF maybe promising in memory-enhancing. However, under certain pathological conditions, such as Alzheimer's disease, HIV-associated dementia or post-ischemic neuronal death, acting as a potent inflammatory mediator and neurotoxin, PAF has been implicated in the pathophysiology of brain injury. So, modulating the metabolism and effects of PAF (e.g., blocking the PAF receptor) may become important strategies of intervention of Alzheimer's disease, HIV-associated dementia or post-ischemic neuronal death.
Study on expression of platelet membrane glycoproteins in cerebral infarction with carotid atherosclerosis

CHEN Qiu-Yue,DING Mei-Ping,JIN Xiao-Ping

2008-01-01

Abstract:Objective To investigate how activating platelet affects on the onset of atherosclerotic cerebral infarction. Methods Positive rates of PAC-1 and CD62P,which are both platelet membrane glycoproteins,were measured by flow cytometry in blood samples while carotid artery were evaluated by color Doppler ultrasound in 76 patients with atherosclerotic cerebral infarction and 53 healthy examination persons. Results The positive rates of PAC-1 and CD62P in the group of cerebral infarction with carotid atherosclerosis were the highest(PAC-1:15.1±5.9,CD62P:16.2±7.3). The positive rates in the cerebral infarction groups no matter with or without carotid atherosclerosis were significantly higher than those in the corresponding control groups(P<0.05),and the rates in the groups with carotid atherosclerosis were significantly higher than those in the groups without carotid atherosclerosis both in cerebral infarction groups and in control groups(P<0.05). In the group of cerebral infarction with carotid atherosclerosis,positive rates of PAC-1 and CD62P in the group with carotid atheromatus plaque were significantly higher than those in the group without atheromatus plaque(P<0.05). In the group of cerebral infarction with carotid atheromatus plaque,positive rates of PAC-1 and CD62P in the group with unstable carotid atheromatus plaque were significantly higher than those in the group with stable plaque(P<0.05). Conclusion The levels of platelet activation were higher in cerebral infarction patients with carotid atherosclerosis,and was much higher in those patients with carotid atheromatus plaque,especially with unstable plaque. The level of platelet activation is related with carotid atherosclerosis as well as cerebral infarction. We suspect activating platelet may play an important role in the onset and progress of cerebral infarction with carotid atherosclerosis.
Pathological Effects of Platelet-Activating Factor and Its Receptor after Cerebral Ischemia/reperfusion Injury in Rats

王岚,张颖冬,徐运,王翀,黄嵘,王晓云,朱文斌

DOI: https://doi.org/10.3969/j.issn.1004-1648.2006.01.011

2006-01-01

Journal of Clinical Neurology

Abstract:Objective To investigate the pathologic neurotoxicity of platelet-activating factor (PAF) and its receptor (PAFR) after local ischemia/reperfusion injury in rat brain and study protective effect on ischemia/reperfusion.Methods Middle cerebral artery occlusion and reperfusion model of rats were established. Then PAF was measured by high performance thin-layer chromatography and PAFR gene expression was detected by RT-PCR after 3 h,6 h,12 h of local ischemia/reperfusion injury. Also, primary mice cortex neurons were culture. Neurons cultured in vitro were divided into three groups: contral group, PAF group and PAF+ receptor inhibitor group. Then cells were stained with PI/calcein for apoptosis.Results After 3 h、6 h、12 h of ischemia/reperfusion injury The PAF content of rats' cortex in ischemic side were (13.71±1.23)ng/g,(17.90±1.14)ng/g and (17.89±1.54)ng/g respectively. The PAFR gene expressions in the cortex after ischemia /reperfusion were (0.5892±0.1222)density,(2.0512±0.1519)density,(2.0168±0.1653)density. PAF content and PAFR gene expressions at 6 h、12 h local ischemia/reperfusion injury were significantly higher than those of the control group and 3 h after ischemia/reperfusion injury(all P 0.01). In vitro, neuron apoptosis rate of PAF group and PAF+ receptor inhibitor group were (41.92±1.39)% and (18.94±1.18)%, which were significantly higher(all P 0.01) than that of control group (10.23±0.59)%.Compare with PAF group, percentage of apoptosis of PAF+ receptor inhibitor group decreased significantly ( P 0.01). Conclusions The neurotoxicity induced by PAF after cerebral ischemia, in which PAF receptor may participate, can be suppressed by PAFR inhibitor. Antagonist of PAFR can protect neuron against injury after ischemia.
[Effect of Platelet-Activating Factor on Long-Term Potentiation in Rat Hippocampal Slices].

Jun Dong,Da-xiang Lu,Liang Yan,Sui-mei Zhang

DOI: https://doi.org/10.3969/j.issn.1000-6834.2005.02.003

2005-01-01

Abstract:AIM:To explore the effect of platelet-activating factor on long-term potentiation in the CA1 region of rat hippocampal slices.METHODS:We recorded the excitatory postsynaptic potentials (EPSPs) and investigated effect of long-term potentiation by PAF in rat hippocampus in vitro.RESULTS:Low doses (1 micromol/L ) of PAF could induce LTP, while higher doses (10-50 micromol/L) of PAF could inhibit induction of LTP. But it couldn't inhibit the LTP induced by subsequent high frequency stimulation and the EPSP of basal. GB of PAF receptor antagonists could prevent the LTP induced by low doses of PAF, and could't inhibit the LTP induced by HFS.CONCLUSION:Higher doses of PAF is an HIV-1-induced neurotoxin, it may contribute to the HAD pathogenesis by inhibition of LTP.
Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis

Sallouha Aidoudi,Andreas Bikfalvi

DOI: https://doi.org/10.1160/TH10-03-0193

Abstract:Platelet factor-4 (PF4), a platelet-derived chemokine, has two important functions in the vasculature. It has a pro-atherogenic role while also having anti-angiogenic effects. The activity of platelet factor-4 (PF4), unlike other chemokines that bind to specific receptors, depends on its unusually high affinity for proteoglycans and other negatively charged molecules. High affinity for heparan sulfates was thought to be central to all of PF4's biological functions. However, other mechanisms have been described such as direct growth factor binding, activation of the CXCR3B chemokine receptor isoform that is present in some vascular cells or binding to lipoprotein-related protein-1 (LRP1). Furthermore, PF4 also binds to integrins with affinities similar to matrix molecules. These interactions may explain the effects of PF4 in healthy and pathological tissues. However, the mechanisms involved in PF4's activity are complex and may depend on a given tissue or localisation. Overall, while much is already known about PF4, its specific role in atherosclerosis and angiogenesis remains still to be clarified.
Do platelets protect the heart against ischemia/reperfusion injury or exacerbate cardiac ischemia/reperfusion injury? The role of PDGF, VEGF, and PAF

Nikita S Voronkov,Leonid N Maslov,Evgeniy V Vyshlov,Alexander V Mukhomedzyanov,Vyacheslav V Ryabov,Ivan A Derkachev,Artur Kan,Svetlana V Gusakova,Alexandra E Gombozhapova,Oleg O Panteleev

DOI: https://doi.org/10.1016/j.lfs.2024.122617

2024-06-15

Abstract:Background: Acute myocardial infarction (AMI) is one of the main causes of death. It is quite obvious that there is an urgent need to develop new approaches for treatment of AMI. Objective: This review analyzes data on the role of platelets in the regulation of cardiac tolerance to ischemia/reperfusion (I/R). Methods: It was performed a search of topical articles using PubMed databases. Findings: Platelets activated by a cholesterol-enriched diet, thrombin, and myocardial ischemia exacerbate I/R injury of the heart. The P2Y12 receptor antagonists, remote ischemic postconditioning and conditioning alter the properties of platelets. Platelets acquire the ability to increase cardiac tolerance to I/R. Platelet-derived growth factors (PDGFs) increase tolerance of cardiomyocytes and endothelial cells to I/R. PDGF receptors (PDGFRs) were found in cardiomyocytes and endothelial cells. PDGFs decrease infarct size and partially abrogate adverse postinfarction remodeling. Protein kinase C, phosphoinositide 3-kinase, and Akt involved in the cytoprotective effect of PDGFs. Vascular endothelial growth factor increased cardiac tolerance to I/R and alleviated adverse postinfarction remodeling. The platelet-activating factor (PAF) receptor inhibitors increase cardiac tolerance to I/R in vivo. PAF enhances cardiac tolerance to I/R in vitro. It is possible that PAF receptor inhibitors could protect the heart by blocking PAF receptor localized outside the heart. PAF protects the heart through activation of PAF receptor localized in cardiomyocytes or endothelial cells. Reactive oxygen species and kinases are involved in the cardioprotective effect of PAF. Conclusion: Platelets play an important role in the regulation of cardiac tolerance to I/R.
Effect of Platelet Activating Factor(PAF) on the collagen induced platelet aggregation in whole blood.

Y Oura,N Sakiyama,R Ueshima,M Higuchi,E Kakishitha,K Nagai

DOI: https://doi.org/10.1055/s-0038-1643481

1987-01-01

Abstract:Studies of platelet aggregation are generally performed in p1ate1et-rich plasma(PRP) by the transmittance method. Recently, impedance aggregometry has been introduced which shows the platelet aggregability in whole blood. We compared the impedance aggregometry in whole blood with the transmittance method in PRP, with regard to collagen induced platelet aggregation. The aggregation rate in whole blood increased with increasing concentration of collagen, but remained unchanged in PRP. The factors which influence the platelet aggregation rate in whole blood were studied. CV-3988, that is the specific antagonist of PAF, acetylsalicylic acid (ASA) and phosphocreatine / creatine phosphokinase (CP/CPK) were used in order to evaluate the contribution of PAF, thromboxane and ADP in whole blood. CV-3988 dose-dependently inhibited platelet aggregation induced by collagen in whole blood, but did not inhibit the aggregation in PRP. ASA(10mM) inhibited the aggregation in whole blood incompletely too, but completely in PRP. And the inhibition of CP/CPK(CP/CPK : 1.5mM/50U/ml) was very weak in whole blood compared to that of other antagonists. The inhibitory effect of CV-3988 was investigated on the collagen induced platelet aggregation in whole blood which was pretreated with ASA ( 1 OmM ) and CP/CPK (1.5mM/50U/ml), resulting in a collagen induced aggregation in whole blood that was not completely inhibited. We conclude that there are some other different factors, which influence platelet aggregation in whole blood, in addition to thromboxane, ADP and PAF.
Platelet-Derived Factor V Is a Critical Mediator of Arterial Thrombosis.

Meiping Ren,Rong Li,Ni Chen,Ningbo Pang,Yongjie Li,Xin Deng,Liqun Wang,Mao Luo,Yan Liu,Haiyan Hao,Yong Liu,Hongmin Sun,Jianbo Wu

DOI: https://doi.org/10.1161/JAHA.117.006345

IF: 6.106

2017-01-01

Journal of the American Heart Association

Abstract:Background-Coagulation factor V (FV) plays a key role in hemostasis, is present in plasma and platelets, and has both pro-and anticoagulant properties; however, the contribution of platelet-derived FV to arterial thrombosis remains undetermined. Methods and Results-Using transgenic mice with various levels of FV gene expression that was restricted to the plasma or platelets, the roles of platelet FV were evaluated in the regulation of arterial thrombosis and platelet activation. Mice with higher levels of platelet FV exhibited faster thrombotic occlusion of the carotid artery after injury compared with mice with lower platelet FV levels. Infusion of platelets with higher levels of FV into transgenic mice with undetectable levels of platelet FV reduced the time to carotid artery occlusion. In contrast, infusion of purified recombinant plasma FV into mice with undetectable platelet FV levels failed to reduce the carotid occlusion times following injury. Evaluation of isolated platelets revealed that platelet-derived FV was critical for the regulation of platelet activation. These effects were associated with an increased level of expression of P-selectin and increased cGMP in platelets. Conclusions-We established that platelet-derived FV is a critical mediator of arterial thrombosis that involves platelet activation.

Influence of Platelet-Activating Factor on Cardiovascular System

The Role of Plateletactivating Factor in Hepatic Ischemiareperfusion Injury and the Protective Effect of Anisodamine

Role of platelet-activating factor receptor in adhesion and invasion of Aggregatibacter actinomycetemcomitans in human umbilical vein endothelial cells

Effects of platelet activating factor on action potentials and potassium channels in guinea-pig ventricular myocytes

Effects of Carvedilol on Homocysteine,endothelin and Von Willebrand Factor in Patients with Unstable Angina Pectoris

Role of platelet activating factor in diagnosis and treatment of acute cerebral infarction

Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients

Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases

[Renal diseases and platelet activating factor]

Therapy for Acute Pancreatitis with Platelet-Activating Factor Receptor Antagonists

Effects of Anisodamine on the Injury of Rat Pulmonary Microvascular Endothelial Cells Induced by Platelet-Activating Factor

Roles of platelet-derived growth factor and platelet-derived growth factor receptors in cardiovascular diseases

Determination of the Platelet Activating Factor in Silicotic Patients and Its Effect on Fibroblasts

Dual Activities of PAF in Central Nervous System and Its Values in Development of New Drugs

Study on expression of platelet membrane glycoproteins in cerebral infarction with carotid atherosclerosis

Pathological Effects of Platelet-Activating Factor and Its Receptor after Cerebral Ischemia/reperfusion Injury in Rats

[Effect of Platelet-Activating Factor on Long-Term Potentiation in Rat Hippocampal Slices].

Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis

Do platelets protect the heart against ischemia/reperfusion injury or exacerbate cardiac ischemia/reperfusion injury? The role of PDGF, VEGF, and PAF

Effect of Platelet Activating Factor(PAF) on the collagen induced platelet aggregation in whole blood.

Platelet-Derived Factor V Is a Critical Mediator of Arterial Thrombosis.